The present invention relates to: * combinations of: component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2) as defined herein, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof； component B: anti-Programmed Cell Death Protein 1 (also referred to as “PD-1” or “CD279” (cluster of differentiation 279)) antibody (anti-PD-1 mAb) as defined herein； in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially； independently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route； * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer； and * a kit comprising such a combination.
